Table 1.

Cytoplasmic YAP1 staining and prostate cancer phenotype.

	Cytoplasmic YAP1 staining (%)
	N	Negative	Weak	Moderate	Strong	P
All cancers	9571	19.1	38.6	38.7	3.5
Tumour stage						<0.0001
pT2	5967	20.2	40.1	37.1	2.5
pT3a	2261	17.4	37.0	40.9	4.8
pT3b-pT4	1308	17.0	34.6	42.7	5.7
Gleason grade						<0.0001
≤3 + 3	1775	27.0	41.0	30.1	1.9
3 + 4	5171	18.1	38.6	39.9	3.4
3 + 4 Tert.5	440	17.0	39.8	42.0	1.1
4 + 3	987	15.3	37.5	42.5	4.8
4 + 3 Tert.5	679	12.8	38.7	42.6	5.9
≥4 + 4	512	19.7	32.2	41.4	6.6
3 + 4 ≤ 5%	1292	20.2	39.2	38.1	2.5	<0.0001
3 + 4 6–10%	1347	17.1	39.7	39.9	3.3
3 + 4 11–20%	1171	18.6	36.6	41.4	3.3
3 + 4 21–30%	608	15.6	40.3	40.6	3.5
3 + 4 31–49%	520	17.1	36.2	41.3	5.4
4 + 3 50–60%	419	16.0	38.2	42.5	3.3
4 + 3 61–80%	375	13.6	38.1	42.1	6.1
4 + 3 > 80%	96	12.5	28.1	54.2	5.2
Lymph node metastasis						0.0237
N0	5656	17.4	38.5	40.2	3.9
N +	648	18.2	32.6	44.3	4.9
Preoperative PSA level (ng/ml)						<0.0001
<4	1104	14.8	36.9	43.7	4.7
4–10	5714	18.4	38.8	39.5	3.3
10–20	1980	22.3	40.1	34.3	3.3
>20	709	23.4	36.5	36.2	3.8
Surgical margin						0.4865
Negative	7522	19.1	38.8	38.7	3.4
Positive	2011	19.3	37.8	38.9	4.0